NCT06641024
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL No drug interventions treatment 1 not_yet_recruiting NCT05292664
Venetoclax Basket Trial for High Risk Hematologic Malignancies treatment 1 recruiting NCT06445803
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL No drug interventions treatment 1 recruiting NCT06343090
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients No drug interventions treatment Not Available recruiting NCT05809284
Determining the Mechanisms of Loss of CAR T Cell Persistence No drug interventions Not Available Not Available recruiting NCT04340154
Study of Sequential CAR-T Cell Treating Leukemia Children No drug interventions treatment 2 active_not_recruiting NCT06389305
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction No drug interventions treatment Not Available not_yet_recruiting NCT03705507
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia treatment 1 / 2 terminated NCT03957915
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia No drug interventions treatment 0 recruiting NCT05705570
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies treatment 1 not_yet_recruiting NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). No drug interventions treatment 1 / 2 recruiting NCT04325841
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children No drug interventions treatment 2 recruiting NCT05066958
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT No drug interventions prevention 1 / 2 unknown_status NCT03389035
Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT No drug interventions treatment 1 / 2 completed NCT05779930
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL No drug interventions treatment 0 not_yet_recruiting NCT06025682
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO No drug interventions Not Available Not Available recruiting NCT06316427
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05310591
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence treatment 1 / 2 recruiting NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies treatment 0 recruiting NCT05745714
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies treatment 1 / 2 not_yet_recruiting NCT06326008
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial No drug interventions treatment 1 not_yet_recruiting NCT04049383
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL No drug interventions treatment 1 recruiting NCT06034561
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia treatment 2 recruiting NCT04224571
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children treatment 2 completed NCT06316856
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 recruiting NCT03515200
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia treatment 1 terminated NCT03573700
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia treatment 1 / 2 active_not_recruiting NCT04888442
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL No drug interventions treatment 1 unknown_status NCT05740449
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies treatment 1 / 2 withdrawn NCT01518517
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia treatment 2 / 3 completed NCT04475731
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse treatment 2 recruiting NCT05137860
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD treatment 4 unknown_status NCT05658640
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies treatment 1 / 2 recruiting NCT04881240
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia treatment 1 recruiting NCT04340167
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children No drug interventions treatment 2 recruiting NCT03751072
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) No drug interventions Not Available Not Available unknown_status NCT01743807
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia No drug interventions treatment 1 terminated NCT00928200
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) treatment 1 terminated NCT04996160
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) treatment 1 recruiting NCT03349281
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL treatment 1 completed NCT04012879
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia No drug interventions treatment 1 unknown_status NCT03575325
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia treatment 2 completed NCT05192889
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax treatment 1 / 2 active_not_recruiting NCT02091245
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML treatment 1 active_not_recruiting